基本信息
views: 433
Career Trajectory
Bio
He is a member of the Early Breast Cancer Trialists’ Cooperative Group steering committee and of the Scientific Advisory Council of the Susan G Komen for the Cure®. He also serves as member of the Breast International Group Executive Board. Currently, Dr. Di Leo and colleagues are studying breast cancers that express estrogen receptors (ER) and HER2, referred to as ER-positive and HER2-positive, respectively. These breast cancers are treated with targeted therapies usually in combination with chemotherapy. Since 2003, Dr. Di Leo has served as Head of the Sandro Pitigliani Medical Oncology Dept. at the Hospital of Prato, Instituto Toscano. He is a member of the Early Breast Cancer Trialists’ Cooperative Group steering committee and of the Scientific Advisory Council of the Susan G Komen for the Cure®. He also serves as member of the Breast International Group Executive Board. Currently, Dr. Di Leo and colleagues are studying breast cancers that express estrogen receptors (ER) and HER2, referred to as ER-positive and HER2-positive, respectively. These breast cancers are treated with targeted therapies usually in combination with chemotherapy.
Research Interests
Papers共 478 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2023)
crossref(2023)
Digestive and Liver Disease (2022): S71-S71
CANCER TREATMENT REVIEWS (2021)
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn